Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an announcement.
Rhythm Biosciences Ltd has issued 31,250 unquoted options under an employee incentive scheme, with each option exercisable at A$0.20 and expiring on 30 November 2027, as notified in an Appendix 3G filing to the ASX. The move underscores the company’s ongoing use of equity-based incentives to attract and retain key staff, aligning employee interests with shareholders and potentially modestly increasing the company’s fully diluted capital base if the options are exercised.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian-listed life sciences company focused on developing diagnostic technologies, particularly in the biosciences and medical diagnostics sector, and its securities trade on the ASX under the code RHY.
Average Trading Volume: 440,832
Technical Sentiment Signal: Buy
Current Market Cap: A$32.69M
See more insights into RHY stock on TipRanks’ Stock Analysis page.